The Max Planck Society for the Advancement of Science (German: Max-Planck-Gesellschaft zur Förderung der Wissenschaften e. V.; abbreviated MPG) is a non-governmental and non-profit association of Research Institutes publicly funded by the federal and the state governments of Germany. Additionally, the Max Planck Society and its Institutes receive third party funding from public and private contributions and from the European Union. The world leading organization is named in honor of its former president, theoretical physicist Max Planck. The 86 Institutes and Research Facilities of the Max Planck Society (as of 2020) conduct basic research in the natural sciences, life sciences, social sciences, and the arts and humanities. They have a total staff of approximately 24,000 permanent employees, including 15,000 scientists, and around 5,000 non-tenured scientists and guests. As of December 31, 2018, the proportion of female employees was 44.4 percent. The Max Planck Society (with its 86 Max Planck Institutes) has a world-leading reputation as a science and technology research organization, with more than 33 Nobel Prizes awarded to its scientists, and is widely regarded as one of the foremost basic research organizations in the world.

Celltheon has been serving the Biotherapeutics industry with innovation and dedication since its founding in 2012. Celltheon was founded as a California Corporation by Amita Goel, a leader in Cell Line Development and Expression Technologies, to develop the next generation in Cell Engineering technologies. Celltheon has patents,

Juno is a clinical-stage company that brings together three of the world’s leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and Seattle Children’s Research Institute – in unique partnership to advance a broad pipeline of breakthrough immunotherapies. With one of the largest ever Series A investments for a biotech startup, Juno will build on the foundation of novel immunotherapies to develop two distinct and complementary platforms – CARs and TCRs.

The King Faisal Specialist Hospital and Research Centre (Arabic: مستشفى الملك فيصل التخصصي ومركز الأبحاث‎) (KFSH&RC) is tertiary referral hospital in Riyadh, the capital city of Saudi Arabia. As a tertiary referral hospital, it offers primary and highly specialized inpatient and outpatient medical care and participates in many clinical and research studies. It is consistently recognized as one of the nation's top hospital specializing in Oncology, Organ Transplantation, Cardiovascular Diseases, Neurosciences and Genetic Diseases. A large portion of the patient population are referrals from other hospitals from across Saudi Arabia as a whole and the surrounding regions. The hospital handles around 10,000 thousand outpatient visits each year and houses over 1,600 beds and has 28 health outreach centers. It has a staff of over 1,000 doctors with over 13,500 total employees of 67 different nationalities.

Rodos BioTarget (RBT) is a biopharmaceutical company developing a targeted drug delivery platform. RBT’s patented TargoSphere® technology enables carrying a broad range of active agents selectively into the center of the immune response - i.e., directly into antigen-presenting cells. RBT currently applies its TargoSphere® technology successfully in various models of infectious diseases caused by viruses like HCV/ Hepatitis C and HIV/ AIDS and by bacteria like in Tuberculosis, Legionellosis, and MRSA. Yet, any disorder that goes along with either overshooting or insufficient immunity caused by antigen-presenting cells - like chronic inflammations, cancers, allergies, and autoimmune diseases - may be addressed by RBT’s TargoSphere® technology.

Shanghai Unicar-Therapy Bio-medicine Technology Co., Ltd. is a company headquartered in Songjiang, China. The firm provides cancer treatment services.

Chugai Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, sale, importation, and exportation of pharmaceuticals. Its operations are carried out through the Domestic and Overseas businesses. The Domestic Business covers the manufacturing, research, and development operations in Japan. The Overseas business comprises of sales and production in Europe, Taiwan and China. The company was founded by Juzo Ueno on March 10, 1925 and is headquartered in Tokyo, Japan.

The University of California is the nation's best public university system, delivering top-notch research and innovation to California (and the world).

Oxford Biomedica (UK) Ltd., part of Oxford Biomedica Plc, is a company headquartered in Oxford, UK. The firm develops novel gene therapy products and treatment for cystic fibrosis.

Boehringer Ingelheim Pharmaceuticals, Inc. manufactures pharmaceuticals products. It develops and markets drugs for the treatment of respiratory, cancer, cardiovascular, immunological and central nervous system diseases. The company was founded in 1971 and is headquartered in Ridgefield, CT.

This is a biotechnology company founded by professor Lee Sung-wook's lab They are working on the development of gene therapy products for liver cancer through the development of gene therapy products. It was selected by the TIPS program and was recognized for excellence in technology.

Neurologix, Inc., a development stage company, engages in the discovery and development of therapeutic treatments for disorders of the brain and central nervous system. The company's treatments are designed as alternatives to conventional surgical and pharmacological treatments. It primarily focuses on gene therapy for treating Parkinson's disease, a neurodegenerative disorder; and epilepsy, a group of diseases associated with recurrent seizures, which is caused by periodic episodes of repetitive, abnormal electrochemical disturbance in the central nervous system, beginning in the brain. The company also focuses on the development of gene transfers for the treatment of neurodegenerative and metabolic disorders, including Huntington's disease, depression, and metabolic syndrome or genetically-based obesity. Neurologix, Inc. was founded in 1999 and is based in Fort Lee, New Jersey.

The Board of Regents of The University of Texas System, a subsidiary of The University of Texas at Austin, is an American company located in Austin, TX. The firm oversees college activities.

Suzhou Shenmei Biological Medicine Co., Ltd., established on 2016-02-23, Business scope includes medical technology,Biological Technology(genetically modified organism,Except human stem cell genetic diagnosis)Technology development in the field of expertise,technical consulting,Technical Services,technology transfer,business inquiries,Business Management Consulting,Financial Advisory,account Serive,chemical reagent(except medical,Diagnostic reagents),Chemical raw materials and products(Removal of hazardous chemicals,Monitor Chemicals,civilian explosives,precursor chemicals)promotion of,Engaged in the import and export of goods and technology.[Items subject to approval by law,Business activities can only be carried out after approval by relevant departments]

Nanjing Legend Biotechnology Co., Ltd. is a private company headquartered in Nanjing, China, that develops tumor cell immunotherapies.

Peking University Shenzhen Hospital is a private company headquartered in Guangdong, China. The firm operates hospitals.